These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 12088684)

  • 1. Promises and pitfalls in the reconstitution of immunity in patients who have HIV-1 infection.
    Gandhi RT; Walker BD
    Curr Opin Immunol; 2002 Aug; 14(4):487-94. PubMed ID: 12088684
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination.
    Barouch DH; Santra S; Schmitz JE; Kuroda MJ; Fu TM; Wagner W; Bilska M; Craiu A; Zheng XX; Krivulka GR; Beaudry K; Lifton MA; Nickerson CE; Trigona WL; Punt K; Freed DC; Guan L; Dubey S; Casimiro D; Simon A; Davies ME; Chastain M; Strom TB; Gelman RS; Montefiori DC; Lewis MG; Emini EA; Shiver JW; Letvin NL
    Science; 2000 Oct; 290(5491):486-92. PubMed ID: 11039923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [HIV vaccination].
    Jablonowski H
    MMW Fortschr Med; 2008 Apr; 150 Spec No 1():68-9. PubMed ID: 19031568
    [No Abstract]   [Full Text] [Related]  

  • 4. Protection against chronic infection and AIDS by an HIV envelope peptide-cocktail vaccine in a pathogenic SHIV-rhesus model.
    Nehete PN; Chitta S; Hossain MM; Hill L; Bernacky BJ; Baze W; Arlinghaus RB; Sastry KJ
    Vaccine; 2001 Dec; 20(5-6):813-25. PubMed ID: 11738745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized controlled trial of HIV therapeutic vaccination using ALVAC with or without Remune.
    Angel JB; Routy JP; Tremblay C; Ayers D; Woods R; Singer J; Bernard N; Kovacs C; Smaill F; Gurunathan S; Sekaly RP
    AIDS; 2011 Mar; 25(6):731-9. PubMed ID: 21330911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progress in the development of an HIV-1 vaccine.
    Letvin NL
    Science; 1998 Jun; 280(5371):1875-80. PubMed ID: 9632379
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rates of HIV immune escape and reversion: implications for vaccination.
    Davenport MP; Loh L; Petravic J; Kent SJ
    Trends Microbiol; 2008 Dec; 16(12):561-6. PubMed ID: 18964018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Towards the development of a therapeutic vaccine for the treatment of HIV-1 infection: are we closer than ever?
    Egan MA
    Expert Rev Vaccines; 2007 Jun; 6(3):289-91. PubMed ID: 17542741
    [No Abstract]   [Full Text] [Related]  

  • 9. Cellular immunity for prevention and clearance of HIV infection.
    Kalams SA
    Curr Mol Med; 2003 May; 3(3):195-208. PubMed ID: 12699357
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV type 1 vaccine-induced cytotoxic T cell responses in phase I clinical trials: detection, characterization, and quantitation.
    McElrath MJ; Siliciano RF; Weinhold KJ
    AIDS Res Hum Retroviruses; 1997 Feb; 13(3):211-6. PubMed ID: 9115806
    [No Abstract]   [Full Text] [Related]  

  • 11. The rationale for immunotherapy in HIV-1 infection.
    Walker BD
    J Acquir Immune Defic Syndr (1988); 1994; 7 Suppl 1():S6-13. PubMed ID: 8182510
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nucleic acid immunization of chimpanzees as a prophylactic/immunotherapeutic vaccination model for HIV-1: prelude to a clinical trial.
    Ugen KE; Boyer JD; Wang B; Bagarazzi M; Javadian A; Frost P; Merva MM; Agadjanyan MG; Nyland S; Williams WV; Coney L; Ciccarelli R; Weiner DB
    Vaccine; 1997 Jun; 15(8):927-30. PubMed ID: 9234550
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune reconstitution in HIV-1-infected patients.
    Imami N; Hardy G; Pires A; Burton C; Pido-Lopez J; Mela C; Gotch F
    Curr Opin Investig Drugs; 2002 Aug; 3(8):1138-45. PubMed ID: 12211404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The critical role of CD4(+) T-cell help in immunity to HIV.
    Heeney JL
    Vaccine; 2002 May; 20(15):1961-3. PubMed ID: 11983254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protection of chimpanzees from high-dose heterologous HIV-1 challenge by DNA vaccination.
    Boyer JD; Ugen KE; Wang B; Agadjanyan M; Gilbert L; Bagarazzi ML; Chattergoon M; Frost P; Javadian A; Williams WV; Refaeli Y; Ciccarelli RB; McCallus D; Coney L; Weiner DB
    Nat Med; 1997 May; 3(5):526-32. PubMed ID: 9142121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytotoxic T lymphocytes and viral evolution in primary HIV-1 infection.
    Price DA; O'callaghan CA; Whelan JA; Easterbrook PJ; Phillips RE
    Clin Sci (Lond); 1999 Dec; 97(6):707-18. PubMed ID: 10585898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cellular HIV-1 immune responses in natural infection and after genetic immunization.
    Calarota SA; Wahren B
    Scand J Infect Dis; 2001; 33(2):83-96. PubMed ID: 11233857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effector cytotoxic T lymphocyte numbers induced by vaccination should exceed levels in chronic infection for protection from HIV.
    Altes HK; Price DA; Jansen VA
    Vaccine; 2001 Oct; 20(1-2):3-6. PubMed ID: 11567737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eradication of HIV-1 latent reservoirs through therapeutic vaccination.
    Pankrac J; Klein K; Mann JFS
    AIDS Res Ther; 2017 Sep; 14(1):45. PubMed ID: 28893280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The value of preserving HIV-specific immune responses.
    Kaufmann DE; Rosenberg ES
    J HIV Ther; 2003 Feb; 8(1):19-25. PubMed ID: 12840711
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.